Title: COVID-19 in Latin America: Contrasting phylodynamic inference with epidemiological surveillance.

Running title: Phylodynamic analysis of COVID-19 in Latin America

Authors: Diana M. Rojas-Gallardo,[1] Sandra C. Garzón-Castaño,[1](https://orcid.org/0000-0002-9547-967X), Natalia Millán[2], Erika V. Jiménez-Posada[4, (http://orcid.org/0000-0002-3737-9427)], Jaime A. Cardona-Ospina.[1,2,3,4*] (https://orcid.org/0000-0003-3996-2293)

Affiliations: [1]Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia. [2]Semillero de Investigación en Infecciones Emergentes y Medicina Tropical, SIEM, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia, [3]Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia. [4]Emerging Infectious Diseases and Tropical Medicine Research Group. Instituto para la Investigación en Ciencias Biomédicas - Sci-Help, Pereira, Risaralda, Colombia.[5]Grupo de Biotecnología-Productos Naturales, Facultad de Tecnología, Universidad Tecnológica de Pereira, Colombia

***Corresponding author:** Jaime A. Cardona-Ospina, Phone +57 311 339 5249, Fundación Universitaria Autónoma de las Américas, Bloque B, Av. de las Américas #98-56 Sector Belmonte, Pereira, Risaralda, Colombia, Postal Code: 660001, e-mail: jaime.cardona@uam.edu.co

Words: 1991 | Abstract: 308 | Figures: 3 | Tables: 1 | Supplementary Tables: 2

Abstract:

Introduction: SARS-CoV-2 infection has represented the one of the largest challenges for humanity. This virus was first detected in Latin America and the Caribbean (LAC) in Brazil in February 26, 2020 and it has revealed important gaps in infectious disease surveillance that must be covered. Phylodynamic analysis is a tool that can help to monitor and adapt traditional surveillance measures in order to cover those. Therefore, this work aims to contrast data driven from epidemiologic surveillance in LAC with parameters inferred from phylodynamic analysis of reported genomes of SARS-CoV-2 across different LAC countries **Methods:** We obtained epidemiological data from daily reports provided by European Centre for Disease Prevention and Control up to 13th May, 2020. We estimated Effective Reproductive Number (Re) and calculated epidemic curves with exponential growth (EG) and maximum likelihood (ML) methods. SARS-CoV-2 phylodynamic in Latin-American was analyzed using sequences reported in GISAID for Central and South America up to May 13th 2020. Sequences were aligned, and ML phylogeny was constructed. Coalescent model Birth Death SIR (serial) was run, and SIR trajectories from the birth-death SIR model were plotted. **Results:** A total of 404,448 cases were reported up to 13th May 2020. Overall reproduction number for Latin America, estimated through the EG and ML methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to 1.311) respectively. Phylodynamic analysis for Latin America showed an overall Re of 1.27 (IC95% 1.07 to 1.49). We did not find statistically significant differences between epidemiological and phylodynamic data at the cut-off time, except for Brazil. **Discussion:** Our results support that epidemiological and genomic surveillance are two complementary approaches. Evidence suggests that even with a low number of sequences proper estimations of Re could be performed. We suggest that countries, especially developing

countries, should consider to add genomic surveillance to their systems for monitoring and adapting epidemiological surveillance of SARS-CoV-2.

Keywords:

SARS-CoV-2, COVID-19, Phylodynamic, Epidemiology, Latin America

52 **Introduction:**

53

54 SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus - 2) infection, called
55 COVID-19, has represented one of the largest challenge for humanity, and has revealed the
56 need for better, more accurate, and more expedite surveillance tools, for improving
57 infectious disease control. SARS-CoV-2 transmissibility across the world has varied
58 widely[1], apparently related with control measures, and intensity of disease surveillance.
59 COVID-19 has revealed deep gaps in our society derived from social inequalities, and has
60 showed the importance of solid evidence based decision making, the need to strength our
61 healthcare systems and to improve infectious disease surveillance.

62

63 After the emergence of SARS-CoV-2 in Wuhan, central China in December 2019, COVID-
64 19 rapidly spread across the world, and was first reported in Latin America and the
65 Caribbean (LAC) on February 26, 2020 in Brazil[1]. This virus belongs to the genus
66 Betacoronavirus of the Coronaviridae family, it has a (+) ssRNA genome of approximately
67 29,903bp, and the genomic information accumulated through its evolution has been used
68 for tracking its molecular relatedness with other coronaviruses, and for estimating
69 transmission networks, epidemic size, and effective reproduction number (Re) [2-5].

70

71 In this context, current available phylogenetic methods can serve as tool for improving
72 infectious disease surveillance. Development of the coalescent theory allows to infer from
73 evolutionary analysis the epidemiologic behavior of a pathogen, especial those rapidly
74 evolving, like RNA virus[6-8]. These analysis can enhance disease surveillance efforts,
75 provide additional data for adapting disease surveillance strategies, and can help to assess

effectiveness of implemented surveillance as well as to estimate the Re, generation time, and epidemic size [9, 10]. This work aims to contrast data driven from epidemiologic surveillance in LAC with parameters inferred from phylodynamic analysis of reported genomes of SARS-CoV-2 across different LAC countries.

Materials and Methods

Epidemiological data source

In order to contrast phylodynamic inference with COVID-19 epidemiological surveillance data , we obtained data published by the European Centre for Disease Prevention and Control [1] until 13th May, 2020. Countries were filtered by continent and only countries belonging to Latin America and the Caribbean region were included. Incident cases and dates of reporting were obtained, as well as fatal cases. We calculated Case Fatality Rates (CFR) = number of reported deaths/number of total cases) X 100, and estimated Re and epidemiologic curves using exponential growth and maximum likelihood methods[11-13].

Estimation of Effective Reproduction Numbers

In order to estimate Re, we estimated the Generation time (GT) using the R package R0 [11]. The distribution of the generation time, considered as the time between a primary infected case and a secondary case, was estimated by Maximun Likelihood using the serial time between infectee/infector pairs published by He et al, 2020 [11, 14]. Then, Re at the beginning of the epidemic, and its evolution through time were estimated using Exponential Growth

100 (EG) and Maximum Likelihood (ML) methods [12, 13, 15]. The time period over which growth
101 is exponential was estimated using the deviance R-squared statistic over a range of possible
102 time periods [11].
103
104 **Dataset for phylodynamic analysis**
105
106 In order to investigate de SARS-CoV-2 phylodynamic in Latin-American, we search for
107 sequences reported in GISAID [16] for Central and South America up to May 13th 2020. We
108 choose only whole genome sequences (>29,900) of the virus with high coverage, and more
109 than 95% of nucleotide base resolved. We conserved identical sequences with different
110 sampling dates and different location and discard identical sequences with same sampling
111 date between countries. Accession IDs, sampling dates and locations of the sequences were
112 obtained, as well as clinical metadata when available. We also generated subgroup datasets
113 for each country reporting at least five sequences.
114
115 **Phylogenetic analyses**
116
117 Sequences were aligned using MAFFT software v7.450 [17] and visually inspected and edited
118 using Bioedit v7.0.5.3. To assess the recombination for the dataset, we employed the
119 pairwise homoplasy index (PHI) test using SplitsTree v4.15.1[18]. Nucleotide substitution
120 model for the alignment was inferred according to the corrected Akaike information
121 criterion (AICc) in jModelTest v2.1.10 [19]. Maximun Likelihood (ML) phylogeny was
122 constructed using PhyML software v3.1[20] and the tree was visualized and edited with
123 FigTree software v1.8.

124

125 **Coalescent analyses**

126

127 For LAC and each country data set, coalescent model Birth Death SIR (serial) [21] was run
128 with *Phylodynamics* package in BEAST v2.6.2.0 [22]. Priors were introduced with BEAUti
129 and all data sets were run with the same prior distribution and value for Molecular clock
130 rate (1.0 (estimated)), Become Uninfectious Rate (Normal (mean=37.0, sigma =1.3)) and
131 Reproductive Number (Log-normal (mean log=0,0, sd log =1.2)). Markov chain Monte
132 Carlo (MCMC) runs of 80 million states sampling every 8,000 steps were computed. The
133 convergence of MCMC chains was checked using Tracer v.1.7.1[23], ensuring that the
134 effective sample size (ESS) values were greater than 300 for each parameter estimated. For
135 LAC data set, the maximum clade credibility (MCC) trees were obtained from the tree
136 posterior distribution using TreeAnnotator after 10% burn-in [23]. To plot SIR trajectories
137 from the birth-death SIR model we used NELSI package for R.

138

139 **Sensitivity analysis**

140

141 We conducted a sensitivity analysis computing the R-squared statistic over a
142 range of possible time periods for exponential growth (begin between days 1 to 39, and
143 ending between days 40 to 79), selecting the best fit for EG and ML analysis. In order to
144 assess the effect of GT distribution variation on Re estimation, we computed the
145 reproduction ratio over a range of chosen generation time distributions with mean between
146 1 to 14 days, assuming fixed standard deviation, and using ML method.

147

148 **Results**

149

150 A total of 404,448 cases were reported up to 13th May 2020, with 23,153 deaths (overall
151 CFR 5.72%). The countries with most cases were: Brazil (177,589 cases), Peru (72,059
152 cases), Mexico (38,324 cases), Chile (31,721 cases) and Ecuador (30,419 cases), while the
153 countries with the highest CFR were Saint Maarteen (19.48%), British Virgin Islands
154 (14.29%), Antigua and Barbuda (12%), Bahamas (11.83%) and Belize (11.11%), Table 1.
155 A total of 124 genomic sequences were retrieved from GISAID library [16], and after quality
156 clearance 76 genomic sequences, from 6 countries, were finally included for analysis
157 (**Supplementary Table 1**).

158

159 Overall reproduction number for Latin America, estimated through the EG and ML
160 methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to 1.311)
161 respectively. The epidemic curve and time dependent analysis is showed in Figure 1. The
162 portion of the epidemic curve that best fitted exponential growth was estimated between
163 2020-02-26 and 2020-04-11 (first 45 days), with a Growth Rate of 11.91%, and a Re of
164 1.95 (IC95% 1.94 to 1.95) and 1.74351(IC95% 1.72 to 1.77) through EG and ML method,
165 respectively. Sensitivity analysis showed that Re remained within the 95%IC only for a
166 small choice of time windows Figure 1c, and that varied significantly across different GT
167 distributions (data not shown).

168

169 For Latin American ML phylogenetic reconstruction, the GTR+I+G was the best model of
170 nucleotide substitution for the data set (substitution rates for every data set is showed in
171 **Supplementary Table 2**). The PHI test did not found statistically significant evidence for

172 recombination (p = 0.01381). The ML tree (Figure 2) shown a star-like topology in which
173 the external arms are longer than the internal without evidence of structure or space related
174 distribution. Phylodynamic analysis for Latin America showed an overall Re of 1.27
175 (IC95% 1.07 to 1.49).
176
177 To properly contrast observed epidemiologic curves with phylodynamic inferences, we
178 performed subgroup analysis including only countries with at least five reported genomic
179 sequences, and estimating epidemiological observed Re up to the date of the last available
180 genomic sequence. Therefore, only four countries were finally included in the subgroup
181 analysis; Brazil (last reported sequence 03-26-2020, 30 days since first case notification),
182 Argentina (last reported sequence 04-19-2020, 44 days since first case notification), Chile
183 (last reported sequence 03-08-2020, 5 days after first case notification) and Costa Rica (last
184 reported sequence 03-25-2020, 18 days after first case notification). Epidemic curves and
185 SIR trajectories for each country are showed in Figure 3.
186
187 Posterior summary of epidemiological and evolutionary parameters are shown in Table 1.
188 When contrasting observed and inferred Re, we did not find statistically significant
189 differences between epidemiological and phylodynamic data at the cut-off time, except for
190 Brazil. Phylodynamic inference showed an Re for Argentina of 1.48 (IC95% 1.19 to 1.79)
191 contrasted with epidemiological Re estimated using EG of 1.39 (IC95%1.36 to 1.41) and
192 ML of 1.29 (IC95% 1.22 to 1.36). For Brazil showed a Re of 1.59 (IC95% 1.18 to 2.03)
193 contrasted with epidemiological Re estimated using EG of 3.03 (IC95% 2.92 to 3.15) and
194 ML of 2.51 (IC95% 2.37 to 2.65). For Costa Rica showed an Re of 2.33 (IC95% 1.02 to
195 3.78) contrasted with epidemiological Re estimated using EG of 2.14 (IC95% 1.84 to 2.48)

196 and ML of 2.09 (IC95% 1.69 to 2.56). And for Chile showed 2.69 (IC95% 1.15 to 4.41)
197 contrasted with epidemiological Re estimated using EG of 0.02 (IC95% 0.00 to 4.51) and
198 ML of 2.87 (IC95% 0.48 to 8.86). Additionally, we found important differences in the
199 number of reported versus inferred prevalent cases. Phylodynamic analysis showed a total
200 of 119 cases in Brazil, 245 cases in Argentina, 58 in Chile, and 61 cases in Costa Rica,
201 contrasted with a total of 2,433; 2,828; 5; 177 cases reported in each country respectively,
202 at the time of cut-off.
203
204 **Discussion:**
205
206 Our results revealed an overall agreement between epidemiological observed data and
207 photodynamically inferred Re, even for Costa Rica with only five reported genomic
208 sequences up to the date of cut off. However, observed and inferred Re for Brazil varied
209 widely among methods. Sensitivity analysis revealed that for obtention of overlapping Re
210 IC95%, GT mean should be between 4.29 and 5.62 (SD range between 4.12 and 7.02),
211 hence suggesting that likely transmission dynamics in this country could be different to
212 those previously reported [14], while the fact that observed and inferred Re were not different
213 among the other countries supports that transmission dynamics are similar to those reported
214 by He et al, 2020[14].
215
216 However, SIR trajectories revealed disagreement in terms of incident cases, total cases and
217 recovered cases. For some countries, recovered cases were higher than incident cases, like
218 for example Argentina and Brazil (Figure 3). We hypothesize that this disagreement could
219 be related with the real origin of the sequences reported from each country and the real date

220 of SARS-CoV-2 introduction. Since most of sequences available when the analysis was
221 performed were reported at the beginning of the epidemic in each country, it is possible that
222 genomic data did not reveal internal transmission networks but external transmission
223 networks from imported cases. This could be supported on the analysis of ML phylogenetic
224 tree, which did not reveal a space related distribution.
225
226 Moreover, SIR trajectories analysis for some countries inferred recovered cases above
227 infected cases. This disagreement with the observed epidemiological data is interpreted by
228 our group as a likely introduction before the epidemiological reported date. In order to
229 support this hypothesis, we are currently performing Time to Most Recent Ancestor
230 Analysis (TMRA) for each country, including new reported sequences for LAC, which up
231 to May 22, 2020 have increased to 326 (complete and with high coverage).
232
233 Finally, our results support that epidemiological and genomic surveillance are two
234 complementary approaches for analysis of transmission and epidemiological patterns.
235 Overall Re estimation for LAC through phylodynamic analysis showed good agreement
236 with observed Re through epidemiological surveillance even when sequences were not
237 available from every country. Evidence suggests that even with a low number of sequences,
238 proper estimations of Re could be performed. This could provide important insights,
239 especially at the beginning of an epidemic when epidemiological surveillance systems are
240 adjusting follow-up and control measures. At the same time, we found that the lack of
241 clinical and epidemiological metadata for reported sequences difficult making
242 phylodynamic inferences. We suggest that countries, especially developing countries,

should consider to add genomic surveillance to their systems for monitoring and adapting epidemiological surveillance of SARS-CoV-2.

Acknowledgements:

We would like to acknowledge Grupo de Investigación SIRIUS, Facultad de Ingenierias, Universidad Tecnológica de Pereira, for providing resources for performing high performance computational analysis. We also want to acknowledge the laboratories that have contributed publicly available genomes via GISAID in Latin America.

252 **References**

253

254 1. European Centre for Disease Prevention and Control. Geographic distribution of
255 COVID-19 cases worldwide. European Centre for Disease Prevention and Control,, 2020.
256 2. Benvenuto D, Giovanetti M, Salemi M, Prosperi M, De Flora C, Junior Alcantara
257 LC, et al. The global spread of 2019-nCoV: a molecular evolutionary analysis. Pathog Glob
258 Health 2020; 114:64-7.
259 3. Dellicour S, Durkin K, Hong SL, Vanmechelen B, Martí-Carreras J, Gill MS, et al.
260 A phylodynamic workflow to rapidly gain insights into the dispersal history and dynamics
261 of SARS-CoV-2 lineages. bioRxiv 2020.
262 4. Li J, Li Z, Cui X, Wu C. Bayesian phylodynamic inference on the temporal
263 evolution and global transmission of SARS-CoV-2. J Infect 2020.
264 5. Scire J, Vaughan TG, Stadler T. Phylodynamic analyses based on 93 genomes.
265 2020.
266 6. Holmes EC. Evolutionary history and phylogeography of human viruses. Annu Rev
267 Microbiol 2008; 62:307-28.
268 7. Pybus OG, Rambaut A, Harvey PH. An integrated framework for the inference of
269 viral population history from reconstructed genealogies. Genetics 2000; 155:1429-37.
270 8. Volz EM, Koelle K, Bedford T. Viral phylodynamics. PLoS Comput Biol 2013;
271 9:e1002947.
272 9. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, et al. Unifying
273 the epidemiological and evolutionary dynamics of pathogens. Science 2004; 303:327-32.

274 10. Rife BD, Mavian C, Chen X, Ciccozzi M, Salemi M, Min J, et al. Phylodynamic
275 applications in 21(st) century global infectious disease research. Glob Health Res Policy
276 2017; 2:13-.
277 11. Obadia T, Haneef R, Boelle PY. The R0 package: a toolbox to estimate
278 reproduction numbers for epidemic outbreaks. BMC Med Inform Decis Mak 2012; 12:147.
279 12. Wallinga J, Lipsitch M. How generation intervals shape the relationship between
280 growth rates and reproductive numbers. Proc Biol Sci 2007; 274:599-604.
281 13. White LF, Pagano M. A likelihood-based method for real-time estimation of the
282 serial interval and reproductive number of an epidemic. Stat Med 2008; 27:2999-3016.
283 14. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
284 shedding and transmissibility of COVID-19. Nat Med 2020; 26:672-5.
285 15. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory
286 syndrome reveal similar impacts of control measures. Am J Epidemiol 2004; 160:509-16.
287 16. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative
288 contribution to global health. Glob Chall 2017; 1:33-46.
289 17. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7:
290 improvements in performance and usability. Mol Biol Evol 2013; 30:772-80.
291 18. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies.
292 Mol Biol Evol 2006; 23:254-67.
293 19. Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new
294 heuristics and parallel computing. Nat Methods 2012; 9:772.
295 20. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New
296 algorithms and methods to estimate maximum-likelihood phylogenies: assessing the
297 performance of PhyML 3.0. Syst Biol 2010; 59:307-21.

298 21. Kuhnert D, Stadler T, Vaughan TG, Drummond AJ. Simultaneous reconstruction of
299 evolutionary history and epidemiological dynamics from viral sequences with the birth-
300 death SIR model. J R Soc Interface 2014; 11:20131106.
301 22. Bouckaert R, Vaughan TG, Barido-Sottani J, Duchêne S, Fourment M,
302 Gavryushkina A, et al. BEAST 2.5: An advanced software platform for Bayesian
303 evolutionary analysis. PLoS computational biology 2019; 15:e1006650.
304 23. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior Summarization
305 in Bayesian Phylogenetics Using Tracer 1.7. Syst Biol 2018; 67:901-4.
306
307

Figure 1. Maximum likelihood phylogenetic relationships between sequences of Latin America data set. Branch lengths estimated as nucleotide substitutions per site.





Figure 2. Epidemic curve (A), Time-dependent analysis of Re (B) in Latin America up to May 13th, 2020, and Sensitivity analysis of exponential growth of epidemic curve (C).

Figure 3. SIR trajectories (A), and epidemic curves (B) for countries with at least five reported genomic sequences. The line corresponds to the epidemic curve estimated through ML method and the dots to incident cases up to the date of the last reported sequence.



369 **Table 1**. Posterior summary of epidemiological and evolutionary parameters.
370

	Molecular clock rate	95% HPD	Become Uninfectious Rate	95% HPD	Reproductive Number	95% HPD
Latin America	0.00014	0.00011-0.00018	36.88	34.38-39.39	1.22	1.0446-1.4156
Argentina	0.00013	0.0006-0.002	36.86	34.25-39.25	1.48	1.022-3.78
Brazil	0.00028	0.00018-0.00038	36.97	43.44-39.50	1.59	1.1792-2.0277
Chile	0.00044	0.00006-0.00094	36.97	34.47-39.57	2.69	1.1455-4.4077
Costa Rica	0.00058	0.00018-0.0010	36.93	34.49-39.58	2.32	1.022-3.78

371

Supplementary Table 1. Substitution model and parameters used to run each data set with BEAST.

Region/Country	Model	Substitutions rates	Parameters
Latin America	Model = GTR+I+G	R(a) [AC] = 0.3454 R(b) [AG] = 0.8055 R(c) [AT] = 0.1965 R(d) [CG] = 0.3182 R(e) [CT] = 2.6714 R(f) [GT] = 1.0000	p-inv = 0.8980 gamma category count = 0 Frequencies = empirical
Argentina	Model = GTR+I	R(a) [AC] = 0.0100 R(b) [AG] = 1.4896 R(c) [AT] = 0.0829 R(d) [CG] = 0.4389 R(e) [CT] = 3.9014 R(f) [GT] = 1.0000	p-inv = 0.7800 gamma category count = 0 Frequencies = empirical
Brazil	Model = GTR+I+G	R(a) [AC] = 0.5540 R(b) [AG] = 0.7814 R(c) [AT] = 0.2557 R(d) [CG] = 0.4662 R(e) [CT] = 2.6314 R(f) [GT] = 1.0000	p-inv = 0.9540 gamma category count = 0 Frequencies = empirical
Chile	GTR	R(a) [AC] = 0.0216 R(b) [AG] = 0.9991 R(c) [AT] = 0.2091 R(d) [CG] = 0.5565 R(e) [CT] = 3.7915 R(f) [GT] = 1.0000	p-inv = 0.0 gamma category count = 0 Frequencies = empirical
Costa Rica	HKY	Estimate	kappa = estimate

Supplementary Table 2. Genomic sequences with dates, countries and accession ID included for phylodynamic analysis.

Accession ID	Sampling date	Country
hCoV-19/Argentina/C121/2020|EPI_ISL_420600|2020-03-07	07/03/2020	**Argentina**
hCoV-19/Argentina/C1374/2020|EPI_ISL_420599|2020-03-18	18/03/2020	**Argentina**
hCoV-19/Argentina/C3013/2020|EPI_ISL_420598|2020-03-22	22/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A001/2020|EPI_ISL_430793|2020-03-01	01/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A004/2020|EPI_ISL_430796|2020-03-27	27/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A005/2020|EPI_ISL_430797|2020-03-27	27/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A006/2020|EPI_ISL_430798|2020-03-28	28/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A007/2020|EPI_ISL_430799|2020-03-30	30/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A009/2020|EPI_ISL_430801|2020-03-31	31/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A011/2020|EPI_ISL_430802|2020-03-31	31/03/2020	**Argentina**
hCoV-19/Argentina/PAIS_A012/2020|EPI_ISL_430803|2020-04-01	01/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A013/2020|EPI_ISL_430804|2020-04-01	01/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A014/2020|EPI_ISL_430805|2020-04-01	01/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A016/2020|EPI_ISL_430807|2020-04-02	02/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A017/2020|EPI_ISL_430808|2020-04-03	03/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A018/2020|EPI_ISL_430809|2020-04-04	04/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A019/2020|EPI_ISL_430810|2020-04-07	07/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A020/2020|EPI_ISL_430811|2020-04-11	11/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A021/2020|EPI_ISL_430812|2020-04-11	11/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A023/2020|EPI_ISL_430814|2020-04-17	17/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A024/2020|EPI_ISL_430815|2020-04-18	18/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A025/2020|EPI_ISL_430816|2020-04-18	18/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A026/2020|EPI_ISL_430817|2020-04-18	18/04/2020	**Argentina**
hCoV-19/Argentina/PAIS_A027/2020|EPI_ISL_430818|2020-04-19	19/04/2020	**Argentina**
hCoV-19/Brazil/SPBR-01/2020|EPI_ISL_412964|2020-02-25	25/02/2020	**Brazil**
hCoV-19/Brazil/SPBR-06/2020|EPI_ISL_414015|2020-02-29	29/02/2020	**Brazil**
hCoV-19/Brazil/SPBR-09/2020|EPI_ISL_416031|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/RJ-314/2020|EPI_ISL_414045|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/CV42/2020|EPI_ISL_429695|2020-03-20	20/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-03/2020|EPI_ISL_414014|2020-03-02	02/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-04/2020|EPI_ISL_414017|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-07/2020|EPI_ISL_416028|2020-03-03	03/03/2020	**Brazil**
hCoV-19/Brazil/RJ-477/2020|EPI_ISL_427300|2020-03-11	11/03/2020	**Brazil**
hCoV-19/Brazil/RJ-477i/2020|EPI_ISL_427301|2020-03-11	11/03/2020	**Brazil**
hCoV-19/Brazil/DFBR-0001/2020|EPI_ISL_426580|2020-03-1	13/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-08/2020|EPI_ISL_416029|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-13/2020|EPI_ISL_416035|2020-03-05	05/03/2020	**Brazil**
hCoV-19/Brazil/BA-510/2020|EPI_ISL_427293|2020-03-06	06/03/2020	**Brazil**

hCoV-19/Brazil/SPBR-12/2020|EPI_ISL_416034|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/DF-615i/2020|EPI_ISL_427294|2020-03-13	13/03/2020	**Brazil**
hCoV-19/Brazil/DF-862/2020|EPI_ISL_427297|2020-03-23	23/03/2020	**Brazil**
hCoV-19/Brazil/DF-891/2020|EPI_ISL_427298|2020-03-22	22/03/2020	**Brazil**
hCoV-19/Brazil/RJ-763/2020|EPI_ISL_427302|2020-03-20	20/03/2020	**Brazil**
hCoV-19/Brazil/DF-861/2020|EPI_ISL_427296|2020-03-23	23/03/2020	**Brazil**
hCoV-19/Brazil/RJ-818/2020|EPI_ISL_427303|2020-03-25	25/03/2020	**Brazil**
hCoV-19/Brazil/RJ-872/2020|EPI_ISL_427304|2020-03-26	26/03/2020	**Brazil**
hCoV-19/Brazil/AL-837/2020|EPI_ISL_427292|2020-03-18	18/03/2020	**Brazil**
hCoV-19/Brazil/CV16/2020|EPI_ISL_429676|2020-03-16	16/03/2020	**Brazil**
hCoV-19/Brazil/SC-769/2020|EPI_ISL_427306|2020-03-10	10/03/2020	**Brazil**
hCoV-19/Brazil/CV4/2020|EPI_ISL_429667|2020-03-09	09/03/2020	**Brazil**
hCoV-19/Brazil/CV6/2020|EPI_ISL_429669|2020-03-13	13/03/2020	**Brazil**
hCoV-19/Brazil/CV21/2020|EPI_ISL_429681|2020-03-16	16/03/2020	**Brazil**
hCoV-19/Brazil/CV32/2020|EPI_ISL_429688|2020-03-17	17/03/2020	**Brazil**
hCoV-19/Brazil/CV31/2020|EPI_ISL_429687|2020-03-17	17/03/2020	**Brazil**
hCoV-19/Brazil/BA-312/2020|EPI_ISL_415105|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-02/2020|EPI_ISL_413016|2020-02-28	28/02/2020	**Brazil**
hCoV-19/Brazil/SPBR-10/2020|EPI_ISL_416032|2020-03-04	04/03/2020	**Brazil**
hCoV-19/Brazil/ES-225/2020|EPI_ISL_415128|2020-02-29	29/02/2020	**Brazil**
hCoV-19/Brazil/SC-766/2020|EPI_ISL_427305|2020-03-10	10/03/2020	**Brazil**
hCoV-19/Brazil/SPBR-11/2020|EPI_ISL_416033|2020-03-03	03/03/2020	**Brazil**
hCoV-19/Brazil/RJ-352/2020|EPI_ISL_427299|2020-03-05	05/03/2020	**Brazil**
hCoV-19/Brazil/AMBR-02/2020|EPI_ISL_417034|2020-03-16	16/03/2020	**Brazil**
hCoV-19/Chile/Santiago-2/2020|EPI_ISL_414580|2020-03-05	05/03/2020	**Chile**
hCoV-19/Chile/Talca-1/2020|EPI_ISL_414577|2020-03-02	02/03/2020	**Chile**
hCoV-19/Chile/Talca-2/2020|EPI_ISL_414578|2020-03-04	04/03/2020	**Chile**
hCoV-19/Chile/Santiago-1/2020|EPI_ISL_414579|2020-03-03	03/03/2020	**Chile**
hCoV-19/Chile/Santiago_op2d1/2020|EPI_ISL_415658|2020-03-06	06/03/2020	**Chile**
hCoV-19/Chile/Santiago_op3d1/2020|EPI_ISL_415660|2020-03-07	07/03/2020	**Chile**
hCoV-19/Chile/Santiago_op4d1/2020|EPI_ISL_415661|2020-03-08	08/03/2020	**Chile**
hCoV-19/Colombia/Antioquia79256/2020|EPI_ISL_417924|2020-03-11	11/03/2020	**Colombia**
hCoV-19/Costa Rica/06/2020|EPI_ISL_434539|2020-03-25	25/03/2020	**Costa Rica**
hCoV-19/Costa Rica/02/2020|EPI_ISL_434535|2020-03-16	16/03/2020	**Costa Rica**
hCoV-19/Costa Rica/04/2020|EPI_ISL_434540|2020-03-18	18/03/2020	**Costa Rica**
hCoV-19/Costa Rica/05/2020|EPI_ISL_434538|2020-03-20	20/03/2020	**Costa Rica**
hCoV-19/Costa Rica/01/2020|EPI_ISL_434533|2020-03-16	16/03/2020	**Costa Rica**
hCoV-19/Peru/010/2020|EPI_ISL_415787|2020-03-10	10/03/2020	**Peru**